Clinical-stage biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has received a Notice of Allowance from the China National Intellectual Property Administration for its patent application covering certain crystalline forms of SDC-1801, a dual TYK2/JAK1 kinase inhibitor.
This development strengthens the company's intellectual property position in China for SDC-1801, which is being developed to treat a range of autoimmune diseases.
The patent, application number 2021800259993, provides protection for various crystalline forms and their preparation methods. Sareum expects the patent to be granted by the end of 2024, pending completion of formalities. Applications in other territories, including the US, Europe and Japan, are currently under review.
SDC-1801, Sareum's lead candidate, is in Phase 1a/b clinical development with an initial focus on psoriasis. The company is also advancing SDC-1802, another TYK2/JAK1 inhibitor, for potential use in cancer immunotherapy.
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Redwire partners with Bristol Myers Squibb for space-based drug research
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Merck acquires CN201 from Curon Biopharmaceutical
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases